- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07792928
A Phase 1 Study to Evaluate the Safety and Effects of a Single Dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults.
25. august 2026 oppdatert av: Shanghai Peptidstar Therapeutics Limited
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants.
The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles?
This study will be a - randomized, double blind, placebo-controlled study.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Studietype
Intervensjonell
Registrering (Antatt)
40
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Laura E Elliot, MBCHb
- Telefonnummer: +64 9 242 3321
- E-post: laura.elliott@momcr.co.nz
Studiesteder
-
-
Auckland
-
Takapuna, Auckland, New Zealand, 0622
- Momentum Clinical Research (MCR)
-
Ta kontakt med:
- Laura E Elliot, MBCHb
- Telefonnummer: +64 9 242 3321
- E-post: laura.elliott@momcr.co.nz
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Body weight ≥ 50 kg for males and ≥ 45 kg for females, and body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
- In good general health as determined by medical history, vital signs, physical examination, 12-lead ECG, laboratory tests (including hematology, blood biochemistry, coagulation function tests, urinalysis, stool routine tests), chest X-ray, etc., with results either within normal limits or assessed by the investigator as not clinically significant.
- Has been fully informed about the study, voluntarily agrees to participate, and has signed the ICF.
- The participant and their sexual partner(s) have no plans for conception from 2 weeks before screening until 6 months after the last dose of the investigational product, and agree to voluntarily using one or more highly effective non-pharmacological contraceptive methods and no intention of donating sperm or eggs during this period.
Exclusion Criteria:
- History or presence of immunological diseases.
- Women who are pregnant or are breastfeeding.
- Any prior or current disease or abnormality that, in the investigator's judgment, is clinically significant and may interfere with the conduct or interpretation of the study, including but not limited to neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, oncologic, pulmonary, immunological, psychiatric, or cerebrovascular conditions.
- Individuals who smoked, consumed coffee, St. John's Wort (hypericum perforatum), grapefruit, pomelo juice, or cranberry juice, and/or engagement in strenuous physical activity within 24 hours prior to dosing, which in the opinion of the investigator may affect drug absorption, distribution, metabolism, or excretion.
- Suspected or known allergy to any component of the investigational product, or any documented history of allergies
- Previous surgical procedures that may affect the results of the clinical study or gastric/abdominal surgery that may impact oral drug absorption; or recent major gastric/abdominal surgery of any kind within 12 weeks prior to screening or during study. With the exception of minor surgeries that in the opinion of the investigator/medical monitor, such as excision of subcutaneous lipomas.
- Having taken any prescription medication, over-the-counter drug, herbal medicine, or dietary supplement within 14 days prior to dosing or within five half-lives of the first administration, except for the condition without impact on the study outcomes as determined by the investigator. Occasional paracetamol less than 1000 mg for minor ailments is permitted if required.
- Non-physiological blood loss or donation of more than 400 mL of blood within 2 months prior to screening, receipt of a blood transfusion within 2 months prior to screening; or plans to donate blood during the study or within 60 days after the last dose.
- Participation in any investigational drug or medical device clinical trial with administration of the investigational product or device intervention within 3 months or five half-lives prior to screening.
- History of alcohol abuse, or consumption of more than 14 alcohol units per week within 6 months prior to screening , or unwillingness to abstain from alcohol during the study, or a positive alcohol test at screening.
- History of smoking (average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening) or unwillingness to abstain from smoking during the study.
- History of drug abuse, use of illicit drugs within 3 months prior to the study, or a positive urine drug screen.
- Infection (including chronic or localized infection) within 7 days prior to screening, or a history of recurrent infections with underlying conditions predisposing to infections, or a history of opportunistic infections.
- Positive test result for any of the following: hepatitis B surface antigen, syphilis-specific antibody, hepatitis C antibody, or human immunodeficiency virus antibody.
- Those who have received any vaccine within 1 month prior to screening, or who are scheduled to receive any vaccine during the study or within 1 month after study completion.
- Having any other factors that, in the opinion of the investigator, may affect the study results or interfere with the participant's participation in the clinical study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HCXT-2001 Tablets - Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Eksperimentell: HCXT-2001 Tablets - Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Placebo komparator: HCXT-2001 Tablets - Placebo Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Eksperimentell: HCXT-2001 Tablets(A) - Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Eksperimentell: HCXT-2001 Tablets(A) - Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Placebo komparator: HCXT-2001 Tablets(A) - Placebo Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Placebo komparator: HCXT-2001 Tablets - Placebo Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Placebo komparator: HCXT-2001 Tablets(A) - Placebo Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine tests
Tidsramme: Day 1 to Day 50
|
Day 1 to Day 50
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum concentration of the drug (Cmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Time to maximum concentration (Tmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Area under the plasma concentration-time curve (AUC, including AUC0-t and AUC0-inf, etc.) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent volume of distribution (Vd/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent clearance (CL/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A)
Tidsramme: Day 1 to day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to day 50
|
|
Plasma elimination half-life (t1/2) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Mean residence time (MRT) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Anti-drug antibodies (ADAs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Day 1 to Day 50
|
|
|
Neutralizing antibodies (Nabs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Tidsramme: Day 1 to Day 50
|
Day 1 to Day 50
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
14. august 2026
Primær fullføring (Antatt)
10. november 2026
Studiet fullført (Antatt)
10. november 2026
Datoer for studieregistrering
Først innsendt
25. august 2026
Først innsendt som oppfylte QC-kriteriene
25. august 2026
Først lagt ut (Faktiske)
28. august 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
28. august 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. august 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HCXT-2001-PS-1-02
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .